HYPOLIPIDEMIC EFFECT OF A NEW ARYLOXY COMPOUND, S-8527, IN EXPERIMENTAL ANIMALS

[摘要] References(15)Cited-By(10)The hypolipidemic action of 1, 1-bis [4'-(1"-carboxy-1"-methylpropoxy)phenyl] cyclohexane (S-8527) was studied in rats, mice and rabbits under various experimental conditions to compare the effects with those of clofibrate. Oral ingestion of S-8527 to normal rats for 7 days lowered serum triglycerides and cholesterol by about 27% at 1 mg/kg and 20% at 3 mg/kg, respectively. The hypolipidemic effect of S-8527 was considered to be twenty to thirty times more potent than that of clofibrate but a hepatomegalic effect of S-8527 was not observed at its effective dose ranging from 1 to 30 mg/kg. S-8527 at 3 mg/kg decreased liver triglyceride concentration by about 20% but the decrease of triglyceride concentration was not observed in clofibrate treated groups. Liver cholesterol concentration was not decreased with any of the doses of S-8527 while clofibrate decreased liver cholesterol concentration by about 20% at 300 mg/kg. However, there were no differences in total content of cholesterol in liver between S-8527 and clofibrate treated groups. With Triton injected rats, a single oral dose of 100 mg/kg of S-8527 depressed the increase of serum triglycerides by about 50% while clofibrate did not. In glycerol-fed rats, S-8527 decreased serum and liver triglycerides more effectively than clofibrate, and in normal mice and cholesterol-fed mice, S-8527 was found to be more active than clofibrate, however the hepatornegalic effect of S-8527 was less than that of clofibrate. Hypolipidemic effects in rabbits were not observed with either S-8527 or clofibrate.

[学科分类] 药理学